JAK2 and Miyoshi myopathy: IL-6, the key cytokine stimulus of the JAK2-STAT3, is overexpressed in MM cells and contributes resistance to major anti-MM agents [24], while blockade of the IL-6 signaling transduction by administration of IL-6-specific monoclonal antibody benefits patients with relapsed or refractory MM by overcoming certain resistance [25].